Question 1

What is cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Cardiomyopathy, familial hypertrophic, 28 is a form of heart muscle disease that primarily affects the structure and function of the heart. This condition is associated with genetic changes in FHOD3 and is inherited in an autosomal dominant pattern. It most commonly presents with abnormal thickening of the heart muscle, particularly in the ventricular septum, which can affect blood flow and heart rhythm. Precise prevalence estimates are not well established, and not all individuals with the genetic variant experience the same set or severity of cardiac symptoms.

Question 2

What are the symptoms of cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

The clinical presentation of cardiomyopathy, familial hypertrophic, 28 is primarily characterized by structural and functional abnormalities of the heart. A large proportion of affected individuals demonstrate asymmetric septal hypertrophy, which is a marked thickening of the wall separating the heart’s chambers. Other features that may be observed include left atrial enlargement and myocardial late gadolinium enhancement, as seen on cardiac imaging studies. Some patients also experience systolic anterior motion of the mitral valve, atrial fibrillation, and signs of left ventricular outflow tract obstruction. In addition, a subset of individuals may develop complications such as stroke, sudden cardiac death, or reduced left ventricular ejection fraction. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Cardiomyopathy, familial hypertrophic, 28 is linked to genetic variants in the FHOD3 gene. FHOD3 plays an important role in the regulation of the cardiac muscle cytoskeleton, and disruptions in its function can lead to abnormal heart muscle structure and function. The condition is inherited in an autosomal dominant pattern, which means that a single copy of the altered gene can contribute to the development of the disease. As a result, each child of an affected individual has a 50% chance of inheriting the genetic variant. That not every individual who inherits the variant will necessarily develop the full spectrum of symptoms, reflecting variable expressivity. Associated genes include FHOD3.

Question 4

How is cardiomyopathy, familial hypertrophic, 28 inherited?

Accepted Answer

cardiomyopathy, familial hypertrophic, 28 follows an autosomal dominant inheritance pattern. This means inheriting just one copy of the altered gene from either parent can cause the condition.

Question 5

How is cardiomyopathy, familial hypertrophic, 28 diagnosed?

Accepted Answer

A definitive diagnosis is achieved through molecular genetic testing that identifies pathogenic variants in FHOD3. Clinical evaluation including detailed cardiac imaging and a review of family history plays an integral role in the diagnostic process. Because many features of this condition can overlap with other cardiac diseases, genetic testing is essential to confirm the diagnosis and to guide management decisions.

Question 6

Are there treatments for cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Currently, management of cardiomyopathy, familial hypertrophic, 28 focuses on supportive care and symptom management. Treatment is tailored to the individual and often involves a multidisciplinary team to address issues such as cardiac rhythm abnormalities and structural heart changes. In the absence of therapies specifically approved for this condition, patients benefit from regular monitoring and interventions aimed at managing symptoms and preventing complications. Genetic counseling is recommended to help families understand the inheritance pattern and discuss appropriate management and family planning options. Patients should discuss treatment options with their healthcare team to determine which therapeutic strategies may be most appropriate for their specific situation.

Question 7

Are there clinical trials for cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Yes, there is currently 1 active clinical trial for cardiomyopathy, familial hypertrophic, 28 registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 8

What are the potential complications of cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Complications of cardiomyopathy, familial hypertrophic, 28 can include serious issues like stroke, sudden cardiac death, and reduced left ventricular ejection fraction. Not everyone with the condition will experience these complications, but they are important to monitor. Regular check-ups with a healthcare provider can help manage these risks.

Question 9

How does cardiomyopathy, familial hypertrophic, 28 affect daily life?

Accepted Answer

Living with cardiomyopathy, familial hypertrophic, 28 can impact daily life in various ways. Some individuals may experience symptoms like shortness of breath or fatigue, which can limit physical activity. It's important for patients to work with their healthcare team to create a management plan that fits their lifestyle and helps them stay active.

Question 10

What is the long-term outlook for someone with cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

The long-term outlook for someone with cardiomyopathy, familial hypertrophic, 28 can vary widely. Many patients live into adulthood, but some may develop complications like arrhythmias or reduced heart function. Regular monitoring and access to specialized care can improve health outcomes and help manage the condition effectively.

Question 11

Should families consider genetic counseling for cardiomyopathy, familial hypertrophic, 28?

Accepted Answer

Yes, families should consider genetic counseling for cardiomyopathy, familial hypertrophic, 28. Genetic counseling can help families understand how the condition is inherited and discuss family planning options. It also provides support in managing the condition and making informed health decisions.

Organ System	Phenotype Count	Example Features
Heart and blood vessels	10	Stroke, Concentric hypertrophic cardiomyopathy, Atrial fibrillation

Research Type	Count	% of Total
Disease patterns and progression	6	27%

Kisho

cardiomyopathy, familial hypertrophic, 28

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

cardiomyopathy, familial hypertrophic, 28

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is cardiomyopathy, familial hypertrophic, 28?

What are the symptoms of cardiomyopathy, familial hypertrophic, 28?

What causes cardiomyopathy, familial hypertrophic, 28?

How is cardiomyopathy, familial hypertrophic, 28 inherited?

How is cardiomyopathy, familial hypertrophic, 28 diagnosed?

Are there treatments for cardiomyopathy, familial hypertrophic, 28?

Are there clinical trials for cardiomyopathy, familial hypertrophic, 28?

What are the potential complications of cardiomyopathy, familial hypertrophic, 28?

How does cardiomyopathy, familial hypertrophic, 28 affect daily life?

What is the long-term outlook for someone with cardiomyopathy, familial hypertrophic, 28?

Should families consider genetic counseling for cardiomyopathy, familial hypertrophic, 28?

Explore clinical features

Recent Publications